Lilly Invests EUR 330 Million in Biopharmaceutical Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Lilly Invests EUR 330 Million in Biopharmaceutical Manufacturing

ePT--the Electronic Newsletter of Pharmaceutical Technology

Eli Lilly plans to invest EUR 330 million ($443.2 million) at its Kinsale location in Ireland to create a new biopharmaceutical commercialization and manufacturing facility. The investment will lead to 200 new jobs, as well as an additional 300 construction roles during the building process.

The facility is planned to be approximately 24,000 ft2 and will produce treatments for illnesses such as cancer and diabetes. In a press release, Lilly’s senior vice-president of global API and dry product manufacturing, Paul Ahern said, “This investment is part of Lilly’s planned growth strategy and proof of our confidence in Lilly’s pipeline of new products, many of which are derived from biotechnology.”

Eli Lilly first established its presence in Kinsale in 1981 and the facility makes APIs for several of the company’s products. The latest announcement marks the second significant investment that the company has made at the site in recent years. In 2006, the company committed to invest EUR 300 million in a biopharmaceutical and new-product commercialization facility. The new facility came on line in 2010, but is still undergoing start-up activities. It is expected to manufacture commercial products in late 2013.

Ireland’s investment agency, IDA Ireland, worked closely with Lilly to attract the investment. According to Ireland’s Minister for Jobs, Enterprise, and Innovation, Richard Bruton, the government has recently outlined a range of measures that will be taken in 2012 to target high-end manufacturing and the health and life science sectors for growth and job creation.

Several other pharmaceutical companies have invested in Ireland recently. Most recently, Abbott Laboratories announced an EUR 85-million ($114.2 million) investment at its manufacturing facility in Sligo at the beginning of February 2012. In September 2011, Pfizer and Merck & Co. invested EUR 145 million ($194.8 million) and EUR 100 million ($134.3 million) in Irish pharmaceutical operations, respectively.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here